AUA 2021 – Trimodality Therapy for Management of Muscle Invasive Bladder Cancer

Dr. Adam Feldman, MD, MPH, urologic oncologist at the Massachusetts General Hospital Department of Urology discusses his presentation from the 2021 American Urological Association’s (AUA) meeting titled “Trimodality Therapy for Management of Muscle Invasive Bladder Cancer” 

Dr. Adam S. Feldman, MD, MPH, is a urologist at the Massachusetts General Hospital Department of Urology. He specializes in the treatment of cancer and related research.

Dr. Feldman is a faculty member and Urologic Oncologist in the Department of Urology at Massachusetts General Hospital, and is Director of the Combined Harvard Urologic Oncology Fellowship. He completed his residency in urology in 2006 and subsequently completed his fellowship in urologic oncology in June 2008. Dr. Feldman focuses his clinical practice in the treatment of genitourinary cancers, using laparoscopic, endoscopic, and open techniques. He focuses his research interests on translational and clinical research in kidney, prostate and bladder cancers. He has received a Prostate Cancer Foundation Young Investigator Award for his work in novel biomarkers in prostate cancer and has been awarded a Physician Research Training Award by the Department of Defense. He is a co-PI on a Department of Defense Synergistic Idea Development Award on the development of conditionally reprogrammed cells in prostate cancer and is a co-investigator on an National Institutes of Health RO1 on metabolomic imaging in prostate cancer. In addition to his translational research work in genitourinary cancer biomarkers, he has worked to develop clinical databases in active surveillance in prostate cancer, use of imaging and fusion biopsy in prostate cancer, surgical and ablative treatments for renal cell carcinoma, and renal mass biopsy.